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191* Magnetic resonance imaging (MRI) as a non-invasive, radiation-
free imaging modality to study the onset and progression of
lung disease in infants and young children with cystic ﬁbrosis
E. Fritzsching1, M. Eichinger2, A. Kopp-Schneider2, M. Sumkauskaite2,
D.-E. Optazaite2, M. Puderbach2, M. Mall1. 1Division of Pediatric Pulmonology
and Cystic Fibrosis Centre, Department of Pediatrics III, Heidelberg, Germany;
2German Cancer Research Center, Department of Radiology, Heidelberg, Germany
Little is known about the onset and spontaneous progression and routine lung
function testing is not available for monitoring of early CF lung disease. The aim of
the present study was to validate pulmonary MRI as a radiation-free, non-invasive
imaging modality to study the onset and progression of lung disease in infants and
young children with CF.
In 34 CF patients (age: 2.5±0.4; 17 f, 17m) MRI (1.5T) was performed in
free breathing. For morphological imaging we used T2w-(HASTE PACE) and
T1w T1-TSE sequences pre and post contrast media in coronal and transversal
orientation. Functional measurements were performed with a 3D-FLASH-sequence
with a temporal resolution of 1.5 s after iv injection of Gadolinium-DTPA. Two
independent radiologists analyzed the images using a dedicated MRI score (range
0−72).
Morphological and functional abnormalities in the CF lung were detected by MRI in
the ﬁrst year of life (MRI score 6.3±1.1; n = 6) and the score increased signiﬁcantly
to 16.2±1.7 (p< 0.05; n = 5) at the age of 4 years. Of note, perfusion defects
preceded morphological abnormalities and were reversible in follow up scans in a
substantial number of patients. Further, MRI scores were reduced after antibiotic
therapy for pulmonary exacerbations (pre treatment: 20.2±7.7vs post treatment
13.0±4.9; p< 0.05).
Our study indicates that MRI of the lung is sensitive to detect abnormal morphology,
function and response to therapy in early CF lung disease. These results suggest
that MRI may be suitable for non-invasive diagnostic monitoring of disease severity
and may serve as a novel endpoint for clinical trials in early CF lung disease.
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192 Late diagnosed cystic ﬁbrosis (CF) in patients with bronchiectasis
and normal sweat tests: the D1152H mutation
J. Miller1, S. Doe1, A. Gascoigne1, S. Bourke1. 1Adult Cystic Fibrosis Centre,
Royal Victoria Inﬁrmary, Newcastle Upon Tyne, United Kingdom
Adult patients with bronchiectasis may have had a diagnosis of CF excluded by
negative sweat tests in childhood. As rarer mutations are identiﬁed some are later
diagnosed as having CF. We report a series of patients with the D1152H mutation,
negative sweat tests, late diagnosed CF and severe lung disease in later life.
Of 220 patients attending our CF centre 5 (2.3%) have F508del/D1152 genotype,
and the diagnosis of CF was not made until a mean age of 55 (range 36−70)
years, although all had bronchiecatisis with Pseudomonas infection. Sweat tests
were normal with a mean chloride of 23 (range 12−38)mmol/L. FEV1 at diagnosis
ranged from 0.35L (11%) to 1.6L (80%); 3 patients were pancreatic insufﬁcient;
mean body mass index was 23 (range 18−37). One man had azoospermia and 4
women had children who were offered genetic advice. Patients improved when given
comprehensive CF treatment. Although symptoms had been relatively mild in early
life all patients progressed to severe lung disease. One patient died of respiratory
failure at age 52 years and one is awaiting lung transplantation at age 59 years.
Patients with bronchiectasis who were investigated for CF by sweat tests in
childhood before DNA analysis was widely available may have had the diagnosis
of CF missed. This particularly applies to the D1152H mutation which is often
associated with a negative sweat test, milder initial disease but progressive lung
disease in later life.
193 Cystic ﬁbrosis (CF) and non-CF bronchiectasis: a cross-sectional
comparison
A. Leonard1, C. Steisel1, A.-S. Aubriot1, V. Godding1, P. Lebecque1. 1Cliniques
Saint-Luc, Universite´ de Louvain, Pediatric Pulmonology & Cystic Fibrosis Unit,
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Introduction: CF is a prototype of severe disease for which well organized and
appropriately funded specialized centres led to considerable improvement of the
prognosis over the last decades. Non-CF bronchiectasis (BX) is caused by many
etiologies. Though globally less severe than CF, it is associated with signiﬁcant
morbidity but does not beneﬁt from similar dedicated care.
Aim: To compare 34 young patients (15F/19M) 6 y with non-CF BX to 34 CF
patients homozygous for the F508 del mutation closely matched for gender and age
(last visit of the year 2010).
Results: Non CF BX etiology (non exclusive) was post infection (12), PCD (11),
congenital heart disease (4), bronchiolitis obliterans (4), immune deﬁciency (3),
laryngeal obstruction (3). CF Patients were smaller but had better pulmonary
function.
Comparative data of the two groups
CF non-CF p
Mean age (y) (± SD) 14.58±7.3 14.57±7.2
Median age at diagnosis (y) 0.19 5 <0.001
Anthropometry (Cole)
Weight (Z score ± SD) −0.45±1.30 −0.26±1.35
Height (Z score ± SD) −0.92±1.22 −0.33±1.29 0.04
BMI (Z score ± SD) 0.14±0.96 −0.19±1.22
Spirometry (Wang-Hankinson)
FVC (% pred. ± SD) 104.5±14.3 89.7±15.8 <0.001
FEV1 (% pred. ± SD) 100.4±16.7 80.3±15.8 <0.001
FEF25−75 (% pred. ± SD) 87.5±42.9 65.1±30 <0.001
Discussion: Though it should not mask important differences in burden of treat-
ment, CF patients carrying a severe genotype were doing better than matched non-
CF patients with BX. Optimal care of non CF-BX would necessitate more adequate
long-term support too.
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Introduction: We outline a novel approach for longitudinal modelling of lung
function with long-term follow-up in which within-patient variation over time is
described by a stationary (mean-reverting) stochastic process, and apply these
techniques to a unique population level dataset of cystic ﬁbrosis patients in
Denmark. The aim is to quantify the long-range changes in lung function in cystic
ﬁbrosis.
Methods: The Danish CF register contains data collected on a monthly basis with up
to 30 years of follow-up. Our statistical analysis framework is that of a linear mixed
effects model with longitudinally structured correlation. Using open-source software
we describe how to partition the variability in the data into three components
(between and within patient, and measurement error) using the empirical variogram.
A parametric model for lung function decline can then be developed. We apply this
approach to explore the effect of age, birth cohort and infection status on lung
function decline.
Results: The dataset contains 70,448 measures on 479 patients seen between 1960
and 2009. The empirical variogram shows slowly decaying long-term correlation
(>15 years) in FEV1, with half of the variability in lung function explained by
within person variation. The mean rate of lung function decline is 0.96% per year
(95%CI 0.86 to 1.07). There is a signiﬁcant cohort effect, and chronic infection
signiﬁcantly increases the rate of lung function decline.
Conclusions: We apply a novel modelling approach to demonstrate that lung
function in early life in the Danish cystic ﬁbrosis population is correlated with
lung function over 15 years later.
